Heterogeneous risk profiles among B3 breast lesions of uncertain malignant potential.


Journal

Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356

Informations de publication

Date de publication:
Apr 2020
Historique:
pubmed: 28 8 2019
medline: 16 4 2020
entrez: 28 8 2019
Statut: ppublish

Résumé

Most cases of breast lesions of uncertain malignant potential (B3) undergo surgical intervention. We aimed to analyze the outcome of B3 lesion subtypes in a large series of screen-detected cases. We screened 2,986 core needle biopsies to classify B3 lesions. Positive predictive values (PPVs) for malignancy were calculated for a comprehensive risk characterization according to clinicopathologic and morphologic variables. B3 lesions comprised 35% atypical ductal hyperplasia (PPV = 20%), 16.7% flat epithelial atypia (PPV = 12%), 22.7% lobular neoplasia (PPV = 16.2%), 9% papillary lesion (PPV = 18.5%), 8.6% phyllodes tumor (PPV = 3.8%), and 8% radial scars (PPV = 4.1%) based on histopathologic diagnosis. Upgrade rates were 15.9% for calcifications, 13.7% for mass lesions, and 16.7% for architectural deformities, with 8.3% of malignant lesions classified as ductal carcinoma in situ and 6.7% as invasive cancers (PPV = 15%). B3 lesions entail a heterogeneous risk of malignancy, and careful radiologic-pathologic correlation is required for optimal treatment.

Sections du résumé

BACKGROUND BACKGROUND
Most cases of breast lesions of uncertain malignant potential (B3) undergo surgical intervention. We aimed to analyze the outcome of B3 lesion subtypes in a large series of screen-detected cases.
METHODS METHODS
We screened 2,986 core needle biopsies to classify B3 lesions. Positive predictive values (PPVs) for malignancy were calculated for a comprehensive risk characterization according to clinicopathologic and morphologic variables.
RESULTS RESULTS
B3 lesions comprised 35% atypical ductal hyperplasia (PPV = 20%), 16.7% flat epithelial atypia (PPV = 12%), 22.7% lobular neoplasia (PPV = 16.2%), 9% papillary lesion (PPV = 18.5%), 8.6% phyllodes tumor (PPV = 3.8%), and 8% radial scars (PPV = 4.1%) based on histopathologic diagnosis. Upgrade rates were 15.9% for calcifications, 13.7% for mass lesions, and 16.7% for architectural deformities, with 8.3% of malignant lesions classified as ductal carcinoma in situ and 6.7% as invasive cancers (PPV = 15%).
CONCLUSION CONCLUSIONS
B3 lesions entail a heterogeneous risk of malignancy, and careful radiologic-pathologic correlation is required for optimal treatment.

Identifiants

pubmed: 31451072
doi: 10.1177/0300891619868301
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115-125

Auteurs

Paolo Orsaria (P)

Department of Breast Surgery, University Campus Bio-Medico, Rome, Italy.

Antonella Grasso (A)

Department of Breast Surgery, University Campus Bio-Medico, Rome, Italy.

Rita Carino (R)

Department of Breast Surgery, University Campus Bio-Medico, Rome, Italy.

Emanuele Caredda (E)

Department of Biomedicine and Prevention, Tor Vergata University Hospital, Rome, Italy.

Matteo Sammarra (M)

Department of Radiology, University Campus Bio-Medico, Rome, Italy.

Carlo Altomare (C)

Department of Radiology, University Campus Bio-Medico, Rome, Italy.

Carla Rabitti (C)

Department of Human Pathology, University Campus Bio-Medico, Rome, Italy.

Gabriella Gullotta (G)

Department of Human Pathology, University Campus Bio-Medico, Rome, Italy.

Giuseppe Perrone (G)

Department of Human Pathology, University Campus Bio-Medico, Rome, Italy.

Francesco Pantano (F)

Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.

Oreste Claudio Buonomo (OC)

Department of Breast Surgery, Tor Vergata University Hospital, Rome, Italy.

Vittorio Altomare (V)

Department of Breast Surgery, University Campus Bio-Medico, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH